The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant ...

ONS-5010 is an investigational ophthalmic formulation of bevacizumab, a vascular endothelial growth factor inhibitor, under development as an intravitreal injection.

NDAQ:TIL) Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT – WATERTOWN, Mass., (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...